AAAAAA
Results:
1-25
|
Results: 25
Authors:
GARTNER U
SCHEULEN ME
CONRADT C
WIEFELSPUTZ J
KRUCK P
AGHABI E
DELBRUCK H
Citation: U. Gartner et al., VALUE OF TUMOR-ASSOCIATED ANTIGEN CA-72-4 COMPARED WITH CEA AND CA-19-9 IN THE FOLLOW-UP OF PATIENTS OPERATED FOR GASTRIC-CARCINOMA, Deutsche Medizinische Wochenschrift, 123(4), 1998, pp. 69-73
Authors:
KORFEL A
SCHEULEN ME
SCHMOLL HJ
GRUNDEL O
HARSTRICK A
KNOCHE M
FELS LM
SKORZEC M
BACH F
BAUMGART J
SASS G
SEEBER S
THIEL E
BERDEL WE
Citation: A. Korfel et al., PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF TITANOCENE DICHLORIDE IN ADULTS WITH ADVANCED SOLID TUMORS, Clinical cancer research, 4(11), 1998, pp. 2701-2708
Authors:
SADONY V
KORBER M
ALBES G
PODTSCHASKE V
ETGEN T
TROSKEN T
RAVENS U
SCHEULEN ME
Citation: V. Sadony et al., CARDIAC TROPONIN-I PLASMA-LEVELS FOR DIAGNOSIS AND QUANTITATION OF PERIOPERATIVE MYOCARDIAL DAMAGE IN PATIENTS UNDERGOING CORONARY-ARTERY BYPASS-SURGERY, European journal of cardio-thoracic surgery, 13(1), 1998, pp. 57-65
Authors:
SCHEULEN ME
Citation: Me. Scheulen, CLINICAL RELEVANCE OF P-GLYCOPROTEIN WITH RESPECT TO THE APPLICATION OF RESISTANCE MODIFIERS, International journal of clinical pharmacology and therapeutics, 36(1), 1998, pp. 41-45
Authors:
HARSTRICK A
MAYER S
HILGER R
MULLER C
DOHMEN D
KLOPPEL R
VANHOEFER U
SCHEULEN ME
WILKE H
SEEBER S
Citation: A. Harstrick et al., COMBINATION THERAPY WITH INFUSIONAL 5-FU AND TOMUDEX FOR PATIENTS (PTS) WITH ADVANCED COLORECTAL-CANCER - A PHASE-I STUDY, Annals of oncology, 9, 1998, pp. 170-170
Authors:
MAYER S
HARSTRICK A
MULLER C
DOHMEN D
HILGER R
SCHEULEN ME
WILKE H
SEEBER S
Citation: S. Mayer et al., PHASE-I STUDY OF TOMUDEX COMBINED WITH PROTRACTED INFUSION OF 5-FU INPATIENTS (PTS) WITH METASTATIC COLORECTAL-CANCER, Annals of oncology, 9, 1998, pp. 633-633
Authors:
KASIMIRBAUER S
OTTINGER HD
BELKA C
STELLBERG W
HALFMEYER K
GEWALTIG I
HARSTRICK A
GROSSEWILDE H
SEEBER S
SCHEULEN ME
Citation: S. Kasimirbauer et al., ANALYSIS OF THE RELATIONSHIP OF P53 STATUS AND RESISTANCE TO CHEMOTHERAPY IN CANCER CELL-LINES AS EVALUATED BY LUMINOMETRIC IMMUNOASSAY (LIA), Tumordiagnostik & Therapie, 19(4), 1998, pp. 113-118
Authors:
HILGER RA
HARSTRICK A
EBERHARDT W
OBERHOFF C
SKORZEC M
BAUMGART J
SEEBER S
SCHEULEN ME
Citation: Ra. Hilger et al., CLINICAL PHARMACOKINETICS OF INTRAVENOUS TREOSULFAN IN PATIENTS WITH ADVANCED SOLID TUMORS, Cancer chemotherapy and pharmacology, 42(2), 1998, pp. 99-104
Authors:
KASIMIRBAUER S
OTTINGER H
MEUSERS P
BEELEN DW
BRITTINGER G
SEEBER S
SCHEULEN ME
Citation: S. Kasimirbauer et al., IN ACUTE MYELOID-LEUKEMIA, COEXPRESSION OF AT LEAST 2 PROTEINS, INCLUDING P-GLYCOPROTEIN, THE MULTIDRUG RESISTANCE-RELATED PROTEIN, BCL-2, MUTANT P53, AND HEAT-SHOCK-PROTEIN-27, IS PREDICTIVE OF THE RESPONSE TO INDUCTION CHEMOTHERAPY, Experimental hematology, 26(12), 1998, pp. 1111-1117
Authors:
CASPER J
FREUND M
HARSTRICK A
SCHEULEN ME
BORNHAUSER M
EHNINGER G
JOSTEN KM
BAUMGART J
SEEBER S
Citation: J. Casper et al., CLINICAL-PHASE-I TRIAL OF HIGH-DOSE TREOSULFAN WITH AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL REINFUSION (PBSCT), Bone marrow transplantation, 21, 1998, pp. 337-337
Authors:
KASIMIRBAUER S
OTTINGER H
WUTTKE M
STELLBERG W
GROSSEWILDE H
SEEBER S
SCHEULEN ME
Citation: S. Kasimirbauer et al., CHRONIC MYELOGENOUS LEUKEMIA - EFFECT OF INTERFERON-ALPHA TREATMENT ON PHAGOCYTIC-ACTIVITY AND CAPACITY OF CIRCULATING NEUTROPHILS, Leukemia research, 22(2), 1998, pp. 115-117
Authors:
ENGERT A
SCHNELL R
KUPPER F
REISER M
ENGELHARD M
WILHELM M
LATHAN B
BALTESENGLER S
WINTERHALTER B
SCHEULEN ME
DEDERICHS B
TESCH H
WORMANN B
DIEHL V
Citation: A. Engert et al., A PHASE-II STUDY WITH IDARUBICIN, IFOSFAMIDE AND VP-16 (IIVP-16) IN PATIENTS WITH REFRACTORY OR RELAPSED AGGRESSIVE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA, Leukemia & lymphoma, 24(5-6), 1997, pp. 513-522
Authors:
PFEIFFER T
KRAUSE U
THOME U
RAJEWSKI A
SKORZEK M
SCHEULEN ME
Citation: T. Pfeiffer et al., TISSUE TOXICITY OF DOXORUBICIN IN FIRST AND 2ND HYPERTHERMIC ISOLATEDLIMB PERFUSION - AN EXPERIMENTAL-STUDY IN DOGS, European journal of surgical oncology, 23(5), 1997, pp. 439-444
Authors:
TRARBACH T
SCHEULEN ME
SCHRODER J
STUSCHKE M
SEEBER S
SCHUTTE J
Citation: T. Trarbach et al., PHASE-II TRIAL OF FIRST-LINE HIGH-DOSE IFOSFAMIDE IN ADVANCED ADULT SOFT-TISSUE SARCOMA, Tumordiagnostik & Therapie, 18(2), 1997, pp. 57-60
Authors:
SCHEULEN ME
KLANIG H
WIEFELSPUTZ JK
KAMPER P
WAGNER B
KONIETZKO N
SEEBER S
Citation: Me. Scheulen et al., PRETHERAPEUTIC EVALUATION OF CYTOKERATIN FRAGMENT-19 (CYFRA-21-1) IN 240 PATIENTS WITH LUNG-CANCER IN COMPARISON TO CARCINOEMBRYONIC ANTIGEN (CEA), NEURON-SPECIFIC ENOLASE (NSE), SQUAMOUS-CELL CARCINOMA ANTIGEN (SCC-AG), TISSUE POLYPEPTIDE ANTIGEN (TPA) AND TISSUE POLYPEPTIDE SPECIFIC ANTIGEN (TPS), Tumordiagnostik & Therapie, 18(1), 1997, pp. 14-19
Authors:
SCHEULEN ME
EBERHARDT W
KLANIG H
KRAUSE B
WIEFELSPUTZ JK
KAMPER P
SEEBER S
Citation: Me. Scheulen et al., CYFRA-21-1 IN THE FOLLOW-UP OF PATIENTS WITH LOCALLY ADVANCED NON-SMALL-CELL LUNG-CANCER DURING AND AFTER NEOADJUVANT CHEMORADIOTHERAPY ANDSURGERY, Tumordiagnostik & Therapie, 18(1), 1997, pp. 20-28
Authors:
EISING EG
GRIES P
EGGERT J
SCHEULEN ME
Citation: Eg. Eising et al., DOES THE MULTIDRUG-RESISTANCE MODULATOR CYCLOSPORINE-A INCREASE THE CARDIOTOXICITY OF HIGH-DOSE ANTHRACYCLINE CHEMOTHERAPY, Acta oncologica, 36(7), 1997, pp. 735-740
Authors:
OTTINGER HD
BEELEN DW
KASIMIRBAUER S
SCHULTEWOLTER T
REBMANN V
GOOS M
SCHEULEN ME
SEEBER S
SCHAEFER UW
GROSSEWILDE H
KLOKE O
Citation: Hd. Ottinger et al., GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) REDUCES THE CAPACITY OFT-CELLS TO EXPRESS PRO-INFLAMMATORY CYTOKINES AND INCREASES SOLUBLE HLA PLASMA-LEVELS IN HUMANS, Blood, 90(10), 1997, pp. 423-423
Authors:
HARSTRICK A
WILKE H
EBERHARDT W
KLAASSEN U
STRUMBERG D
KORN M
SCHEULEN ME
BAUMGART J
SEEBER S
Citation: A. Harstrick et al., A PHASE-I DOSE-ESCALATION TRIAL OF INTRAVENOUS TREOSULFAN IN REFRACTORY CANCER, Onkologie, 19(2), 1996, pp. 153-156
Authors:
SCHRODER J
ESTEBAN M
MULLER MR
KASIMIRBAUER S
BAMBERGER U
HECKEL A
SEEBER S
SCHEULEN ME
Citation: J. Schroder et al., MODULATION OF MULTIDRUG-RESISTANCE BY BIBW22BS IN BLASTS OF DE-NOVO OR RELAPSED OR PERSISTENT ACUTE MYELOID-LEUKEMIA EX-VIVO, Journal of cancer research and clinical oncology, 122(5), 1996, pp. 307-312
Authors:
HARSTRICK A
VANHOEFER U
SCHLEUCHER N
SCHROEDER J
BAUMGART J
SCHEULEN ME
WILKE H
SEEBER S
Citation: A. Harstrick et al., ACTIVITY OF N-BENZYL-ADRIAMYCIN-14-VALERATE (AD198), A NEW ANTHRACYCLINE DERIVATE, IN MULTIDRUG-RESISTANT HUMAN OVARIAN AND BREAST-CARCINOMA CELL-LINES, Anti-cancer drugs, 6(5), 1995, pp. 681-685
Authors:
PFEIFFER T
KRAUSE U
THOME U
SCHEULEN ME
EIGLER FW
Citation: T. Pfeiffer et al., DOSE-RELATED TISSUE TOXICITY OF ADRIAMYCIN IN THE ISOLATED LIMB PERFUSION - AN EXPERIMENTAL-STUDY IN DOGS, British Journal of Surgery, 82, 1995, pp. 119-119
Authors:
BUDACH W
BUDACH V
STUSCHKE M
SCHMAUDER B
REIPKE P
SCHEULEN ME
Citation: W. Budach et al., EFFICACY OF IFOSFAMIDE, DACARBAZINE, DOXORUBICIN AND CISPLATIN IN HUMAN SARCOMA XENOGRAFTS, British Journal of Cancer, 70(1), 1994, pp. 29-34
Authors:
KATH R
HOFFKEN K
OTTE C
METZ K
SCHEULEN ME
HULSKAMP F
SEEBER S
Citation: R. Kath et al., THE NEU-ONCOGENE PRODUCT IN SERUM AND TISSUE OF PATIENTS WITH BREAST-CARCINOMA, Annals of oncology, 4(7), 1993, pp. 585-590
Authors:
BEELEN DW
SAYER HG
FRANKE M
SCHEULEN ME
QUABECK K
MOHNKE M
OIDTMANN M
SCHAEFER UW
Citation: Dw. Beelen et al., CONSTANT INTRAVENOUS PENTOXIFYLLINE INFUSIONS IN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS - RESULTS OF A DOSE-ESCALATION STUDY, Bone marrow transplantation, 12(4), 1993, pp. 363-370
Risultati:
1-25
|